Site is Being Upgraded

Molecular therapy for pulmonary arterial hypertension: Sildenafil [Brand name: Revatio, Viagra and others], a cGMP-specific phosphodiestrase type 5 inhibitor used in the treatment of erectile dysfunction and pulmonary hypertension, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 17/January/2018, 9.28 am

Molecular therapy for inflammation and arthritis: Melatonin[N-Acetyl-5-Methoxy tryptamine], a hormone that regulates sleep and wakefulness, increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 17/January/2017, 5.50 am
January 17, 2018
Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Lovastatin, Epicatechin and Matrine (LSEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 17/January/2018, 9.56 am
January 17, 2018
Show all

What they say: 

A study from the University of California, La Jolla, California, USA shows that Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November  2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054],  by Prof. Thistlethwaite PA, Li X and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Molecular therapy for pulmonary arterial hypertension: Sildenafil [Brand name: Revatio, Viagra and others], a cGMP-specific phosphodiesterase type 5 inhibitor used in the treatment of erectile dysfunction and pulmonary hypertension, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3


Significance of the study:  

Sildenafil has been shown to aid in the treatment of pulmonary arterial hypertension. However, its mechanism of action is far from understood. 

This study suggests, for the first time, that Sildenafil, by increasing the expression of its target gene, it may decrease, in dose-dependent manner, the expression of Notch3 and its target gene Hes-5 (Fig.1). Thereby, it may inhibit and promote, respectively, proliferation and differentiation of smooth muscle cells. And, thereby, prevent pulmonary hypertension (Figure 1).  Thus, pharmacological formulations encompassing “Sildenafil  or its analogues, either alone or in combination with other drugs,” may be used to treat pulmonary arterial hypertension (Figure 2).

Figure 1. Mechanistic insights into how Sildenafil inhibits the development of pulmonary hypertension through regulation of its target genes

Figure 2. The chemical structure of Sildenafil


Details of the research findings: 

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Undisclosed mechanistic information: How Sildenafil decreases the expression of Notch3 and its target gene

Amount: $500#

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References: 

Web: http://genomediscovery.org or http://newbioideas.com/

CitationBoominathan, L.,  Molecular therapy for pulmonary arterial hypertension: Sildenafil [Brand name: Revatio, Viagra and others], a cGMP-specific phosphodiestrase type 5 inhibitor used in the treatment of erectile dysfunction and pulmonary arterial hypertension, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 17/January/2018, 9.27 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, drop us a line at info@genomediscovery.org

Comments are closed.